Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of its IT systems and processes.
The leading global contract research organization, which focuses on supporting pharmaceutical and biotech partners in all phases of drug development, has received the ISO 27001:2013 certification for its Information Security Management System (ISMS).
ISO 27001:2013 is an internationally recognized security standard published by the International Organization for Standardization (ISO). This certification demonstrates BioAgilytix’s alignment with international information security best practices.
The initiative validated BioAgilytix’s commitment to ensuring the confidentiality, integrity and availability of proprietary client data managed by the company.
Sean Blake, Chief Information Officer at BioAgilytix, said: “ISO 27001 is a high standard of accreditation when it comes to security measures and required a tremendous effort by our team, so we are delighted to achieve it. Putting the security infrastructure and safeguards in place to help protect our clients’ data as well as our own company infrastructure is the only responsible decision to make in the current environment.”
“It ensures that as a clinical development partner, we continue to meet the highest IT security and privacy standards. It also provides additional peace of mind to our clients that we are a trusted partner, doing everything possible to help ensure that their information, interests and data are kept secure.”
This is the latest accreditation which BioAgilytix has secured for its work in protecting its systems and client data.
BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across several industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit bioagilytix.com.